北京商报讯（记者 丁宁）2月9日晚间，惠泰医疗（688617）发布公告称，基于对行业前景和公司未来 发展的信心，以及对公司长期投资价值的认可，为了维护广大投资者利益，增强投资者对公司的投资信 心，同时为了进一步建立健全公司长效激励机制，促进公司健康可持续发展，公司拟以自有资金通过上 交所交易系统以集中竞价交易方式回购部分公司股票，并在未来适宜时机将回购股份全部用于员工持股 计划或股权激励，回购资金总额不低于1.5亿元（含），不超过2亿元（含）。 ...

证券代码：688617 证券简称：惠泰医疗 公告编号：2026-004 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 深圳惠泰医疗器械股份有限公司 关于以集中竞价交易方式回购股份方案 暨回购报告书 重要内容提示： ● 回购股份金额：回购资金总额不低于人民币1.5亿元（含），不超过人民币 2亿元（含）。 ● 回购股份资金来源：自有资金 ● 回购股份用途：本次回购的股份将在未来适宜时机用于员工持股计划或股 权激励，并在公司披露股份回购实施结果暨股份变动公告日之后的三年内予以转 让；若公司本次回购的股份未能在上述三年内转让完毕，公司将依法履行减少注 册资本的程序，未转让股份将予以注销。如国家对相关政策作出调整，则本回购 方案按调整后的政策实行。 ● 回购股份价格：不超过人民币315元/股（含），该价格不高于公司董事会 通过回购决议前30个交易日公司股票交易均价的150%。 ● 相关股东是否存在减持计划： 公司董事、高级管理人员、控股股东、实际控制人及一致行动人、持股 5%以上 的股东在董事会通过回购决议之日的未来3个月、未来6 ...

证券代码：688617 证券简称：惠泰医疗 公告编号：2026-003 特此公告。 深圳惠泰医疗器械股份有限公司董事会 深圳惠泰医疗器械股份有限公司（以下简称"公司"）第三届董事会第三次 会议通知于 2026 年 2 月 9 日发出并送达全体董事，全体董事同意豁免本次会议 的提前通知时限要求。本次会议于 2026 年 2 月 9 日以现场结合通讯方式召开， 会议应到董事 9 人，实到董事 9 人，出席董事占应出席人数的 100%。本次会议 的召集、召开及表决程序符合《中华人民共和国公司法》等有关法律、行政法规、 规范性文件和《深圳惠泰医疗器械股份有限公司章程》的规定，会议决议合法有 效。经与会董事审议和表决，会议形成决议如下： 一、 审议通过《关于以集中竞价交易方式回购股份方案的议案》 董事会认为，本次回购公司股份方案设计合理，有利于维护广大投资者利益， 增强投资者对公司的投资信心，建立健全公司长效激励机制，促进公司健康可持 续发展，全体董事一致同意该事项。 具体内容详见公司同日在上海证券交易所网站（www.sse.com.cn）披露的《深 圳惠泰医疗器械股份有限公司关于以集中竞价交易方式回购股份方案暨回购报 ...

每经AI快讯，惠泰医疗2月9日晚间发布公告称，公司第三届董事会第三次会议于2026年2月9日以现场 结合通讯方式召开。会议审议了《关于以集中竞价交易方式回购股份方案的议案》。 每经头条（nbdtoutiao）——美国名校毕业刚回国，26岁"金少"空降成董事长和总经理，父母隐退！A股 多位"00后"执掌要职，"不负投资者"成重大考验 （记者 张明双） ...

每经AI快讯，2月9日，惠泰医疗(688617.SH)公告称，公司计划通过集中竞价交易方式回购股份，资金 总额不低于1.5亿元，不超过2亿元，用于员工持股计划或股权激励。回购价格不超过315元/股，期限为 自董事会审议通过之日起10个月内。公司董事、高级管理人员、控股股东等在未来3个月、6个月无明确 的减持计划。 ...

惠泰医疗公告，拟以1.5亿元-2亿元回购公司股份，回购价格不超过315元/股。 ...

截至2026年1月30日收盘，惠泰医疗（688617）报收于232.0元，较上周的242.5元下跌4.33%。本周，惠 泰医疗1月26日盘中最高价报245.45元。1月26日盘中最低价报231.0元。惠泰医疗当前最新总市值327.19 亿元，在医疗器械板块市值排名6/127，在两市A股市值排名647/5184。 本周关注点 深圳惠泰医疗器械股份有限公司于2025年12月9日至2026年1月28日期间，通过集中竞价交易方式累计回 购股份1,015,738股，占公司总股本的0.7202%，回购价格区间为231.00元/股至264.27元/股，支付资金总 额24,995.13万元。本次回购股份用于员工持股计划或股权激励，资金来源为公司自有资金，回购方案已 实施完毕。回购后公司股权分布仍符合上市条件，未导致控制权变更。已回购股份将在三年内按规定转 让，若未完成转让将依法注销。 公司公告汇总：惠泰医疗回购股份1,015,738股，占总股本0.7202%。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 公司公告汇总 ...

Group 1 - The company is currently selling vascular intervention and some electrophysiological mapping consumables to the EU market through a distribution model [1] - The relevant products have obtained CE certification [1] - The revenue from this market accounts for a relatively low proportion of the company's overall revenue [1]

Key Highlights - Tianqi Co., Ltd. participated in financing for Galaxy General Robotics, acquiring up to 0.38% equity [1] - Hualan Vaccine has no vaccine products available for the prevention of Nipah virus [1] - Aisen Co., Ltd. plans to invest 2 billion yuan to build an integrated circuit materials manufacturing base in East China [1] - Beixin Road and Bridge won a contract for a project worth 1.221 billion yuan [1] - Yongding Co., Ltd. expects a net profit increase of 225.66% to 388.48% in 2025 [1] - Puxin Co., Ltd. intends to acquire a 5% stake in Liyuan Fluororesin for 240 million yuan [1] - Huatai Medical has repurchased 0.7202% of its shares [1] - Dayi Long plans to reduce its stake by no more than 3% [1] - Dongcai Technology's actual controller and vice chairman, Xiong Haitao, has been detained [1] - Yichang Technology's actual controller, Xiong Haitao, is under investigation and has been detained [1] Project Investments - Nord Co., Ltd. plans to invest 168 million yuan to upgrade production line equipment for Qinghai Electronics [1] - Aisen Co., Ltd. is set to invest 2 billion yuan in a manufacturing base for integrated circuit materials [1] Contract Awards - Jintanglang Co., Ltd. won a contract for the interior decoration and weak current intelligent engineering of a new hotel project [1] - Beixin Road and Bridge secured a contract worth 1.221 billion yuan [1] - Huakang Clean won a project worth 54.88 million yuan [1] Earnings Forecasts - New Meixing Co., Ltd. expects a net profit growth of 160.76% to 204.96% in 2025 [1] - Hongxin Electronics anticipates a net profit of 110 million to 150 million yuan in 2025, a year-on-year increase of 93.61% to 164.01% [1] - Yongding Co., Ltd. forecasts a net profit increase of 225.66% to 388.48% in 2025 [1] - Zhenlei Technology expects a net profit increase of 529.64% to 642.26% in 2025 [1] - Ningbo Fubang anticipates a net profit growth of 3099.59% to 4379.43% in 2025 [1] Share Acquisitions - Puxin Co., Ltd. plans to acquire a 5% stake in Liyuan Fluororesin for 240 million yuan [1] - Yingxin Development intends to acquire 60% equity in Changxing Semiconductor [1] Share Buybacks - Jingji Zhino has repurchased 5.438 million shares [2] - Huatai Medical has repurchased 0.7202% of its shares [2] Share Reductions - Baida Precision plans to reduce its stake by no more than 2% [2] - Dayi Long intends to reduce its stake by no more than 3% [2] - Zhishang Technology's Liu Dongsheng and Liu Dongli plan to reduce their stakes by no more than 3% [2] - Shichuang Securities' City Power plans to reduce its holdings by no more than 27.245 million A-shares [2] - Pianzaihuang's Jiulongjiang Group plans to increase its holdings by 300 million to 500 million yuan [2] Other News - Dongcai Technology's actual controller and vice chairman, Xiong Haitao, has been detained [2] - Jingpin Special Equipment has been banned from participating in procurement activities for military supplies for three years [2] - Yichang Technology's actual controller, Xiong Haitao, is under investigation and has been detained [2]

Summary of Key Points Core Viewpoint - On January 28, a total of 14 companies announced 15 stock repurchase updates, indicating a trend of companies engaging in buyback programs to enhance shareholder value [1]. Group 1: First Disclosure of Buyback Plans - Two companies, Greenmei and Davi Co., disclosed their stock repurchase plans for the first time, with proposed buyback amounts not exceeding 3.03 million and 0.23 million respectively [1]. Group 2: Approval of Buyback Plans by Shareholders - Three companies, New Open Source, Guangdong Hongtu, and Guangji Pharmaceutical, had their buyback plans approved by shareholders, with the highest proposed repurchase amounts being 50 million, 18.10 million, and 0.42 million respectively [1]. Group 3: Progress of Buyback Implementation - The companies with the highest buyback amounts in progress include Heng Rui Pharmaceutical, Jingji Agricultural, and Xingfa Group, with repurchase amounts of 605 million, 94.46 million, and 65.54 million respectively [1]. Group 4: Completed Buybacks - The companies that have completed their buybacks with the highest amounts are Huitai Medical, Xiye Co., and Aopu Technology, with completed repurchase amounts of 250 million, 7.01 million, and 0.85 million respectively [1].